Retargeting polymer-coated adenovirus to the FGF receptor allows productive infection and mediates efficacy in a peritoneal model of human ovarian cancer

Journal of Gene Medicine

Volumn 10, Issue 3, 2008, Pages 280-289

  Green, Nicola K ^a   Morrison, Joanne ^b   Hale, Sarah ^c   Briggs, Simon S ^b   Stevenson, Mark ^b   Subr, Vladimir ^c   Ulbrich, Karel ^d   Chandler, Lois ^e   Mautner, Vivien ^f   Seymour, Leonard W ^b   Fisher, Kerry D ^a  

^a Hybrid Systems Ltd   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NHS BLOOD AND TRANSPLANT   (United Kingdom)

^d INSTITUTE OF MACROMOLECULAR CHEMISTRY   (Czech Republic)

^e Tissue Repair Company   (United States)

^f UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Adenovirus; Gene delivery; Gene therapy; Targeting

Indexed keywords

FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR RECEPTOR; LIGAND; POLY[N (2 HYDROXYPROPYL)METHACRYLAMIDE]; VIROTHERAPY AGENT;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GENE THERAPY; CELL INTERACTION; CONTROLLED STUDY; DRUG EFFICACY; DRUG TARGETING; ERYTHROCYTE; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; OVARY CANCER; PERITONEUM ADHESION; PRIORITY JOURNAL; PROTEIN BINDING; VIROTHERAPY; VIRUS PARTICLE;

ACRYLAMIDES; ADENOVIRIDAE; ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; OVARIAN NEOPLASMS; PERITONEAL NEOPLASMS; POLYMERS; RECEPTORS, FIBROBLAST GROWTH FACTOR; TRANSDUCTION, GENETIC; TRANSGENES; TUMOR CELLS, CULTURED;

ADENOVIRIDAE;

EID: 40549116345     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1121     Document Type: Article

References (32)

1. Parker AL, et al. Influence of coagulation factor zymogens on the infectivity of adenoviruses pseudotyped with fibers from subgroup D. J Virol 2007; 81: 3627-3631.
2. Lockley M, et al. Activity of the adenoviral E1A deletion mutant d1922-947 in ovarian cancer: comparison with E1A wild-type viruses, bioluminescence monitoring, and intraperitoneal delivery in icodextrin. Cancer Res 2006; 66: 989-998.
3. Zeimet AG, Marth C. Why did p53 gene therapy fail in ovarian cancer? The Lancet Oncol 2003; 4: 415-422.
4. Ripamonti C, De Conno F, Ventafridda V, Rossi B, Baines MJ. Management of bowel obstruction in advanced and terminal cancer patients. Ann Oncol 1993; 4: 15-21.
5. Reynolds P, Dmitriev I, Curiel D. Insertion of an RGD motif into the HI loop of adenovirus fiber protein alters the distribution of transgene expression of the systemically administered vector. Gene Ther 1999; 6: 1336-1339.
6. Kirkman W 3rd, et al. Transduction and apoptosis induction in the rat prostate, using adenovirus vectors. Hum Gene Ther 2001; 12: 1499-1512.
7. Vigne E, et al. RGD inclusion in the hexon monomer provides adenovirus type 5-based vectors with a fiber knob-independent pathway for infection. J Virol 1999; 73: 5156-5161.
8. Wickham TJ, Carrion ME, Kovesdi I. Targeting of adenovirus penton base to new receptors through replacement of its RGD motif with other receptor-specific peptide motifs. Gene Ther 1995; 2: 750-756.
9. Meulenbroek RA, Sargent KL, Lunde J, Jasmin BJ, Parks RJ. Use of adenovirus protein IX (pIX) to display large polypeptides on the virion - generation of fluorescent virus through the incorporation of pIX-GFP. Mol Ther 2004; 9: 617-624.
10. Lyons M, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther 2006; 14: 118-128.
11. Jiang H, Wang Z, Serra D, Frank MM, Amalfitano A. Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. Mol Ther 2004; 10: 1140-1142.
12. Stallwood Y, Fisher KD, Gallimore PH, Mautner V. Neutralisation of adenovirus infectivity by ascitic fluid from ovarian cancer patients. Gene Ther 2000; 7: 637-643.
13. Shayakhmetov DM, Gaggar A, Ni S, Li ZY, Lieber A. Adenovirus binding to blood factors results in liver cell infection and hepatotoxicity. J Virol 2005; 79: 7478-7491.
14. Schiedner G, et al. A hemodynamic response to intravenous adenovirus vector particles is caused by systemic Kupffer cell-mediated activation of endothelial cells. Hum Gene Ther 2003; 14: 1631-1641.
15. Alemany R, Suzuki K, Curiel DT. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 2000; 81: 2605-2609.
16. O'Riordan CR, et al. PEGylation of adepovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther 1999; 10: 1349-1358.
17. Croyle MA, et al. PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile. Gene Ther 2005; 12: 579-587.
18. Fisher KD, et al. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. Gene Ther 2001; 8: 341-348.
19. Croyle MA, Yu QC, Wilson JM. Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions. Human Gene Ther 2000; 11: 1713-1722.
20. Green NK, et al. Extended plasma circulation time and decreased toxicity of polymer-coated adenovirus. Gene Ther 2004; 11: 1256-1263.
21. Rancourt C, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 2455-2461.
22. Roghani M, Moscatelli D. Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 1992; 267: 22156-22162.
23. Rogers BE, et al. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther 1997; 4: 1387-1392.
24. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol 2005; 79: 1992-2000.
25. Eylar EH, Madoff MA, Brody OV, Oncley JL. The contribution of sialic acid to the surface charge of the erythrocyte. J Biol Chem 1962; 237: 1992-2000.
26. Murakami P, McCaman MT. Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent dye. Anal. Biochem. 1999; 274: 283-288.
27. Rogers BE, Douglas JT, Ahlem C, Buchsbaum DJ, Frincke J, Curiel DT. Use of a novel cross-linking method to modify adenovirus tropism. Gene Ther 1997; 4: 1387-92.
28. Rancourt C, Rogers BE, Sosnowski BA, et al. Basic fibroblast growth factor enhancement of adenovirus-mediated delivery of the herpes simplex virus thymidine kinase gene results in augmented therapeutic benefit in a murine model of ovarian cancer. Clin Cancer Res 1998; 4: 2455-61.
29. Roghani M, Moscatelli D. Basic fibroblast growth factor is internalized through both receptor-mediated and heparan sulfate-mediated mechanisms. J Biol Chem 1992; 267: 22156-62.
30. Wiethoff CM, Wodrich H, Gerace L, Nemerow GR. Adenovirus protein VI mediates membrane disruption following capsid disassembly. J Virol 2005; 79: 1992-2000.
31. Eylar EH, Madoff MA, Brody OV, Oncley JL. The contribution of sialic acid to the surface charge of the erythrocyte. J Biol Chem 1962; 237: 1992-2000.
32. Ballinger MD, et al. Semirational design of a potent, artificial agonist of fibroblast growth factor receptors. Nat Biotechnol 1999; 17: 1199-1204.